The raised guidance and accelerating Adjusted EBITDA growth (44% in Q2) signal strong operational momentum and successful integration of the Amedisys/LHC branches. Monitor the Q3 earnings call for updates on the Community Living divestiture cash deployment and any further debt paydown or share repurchase activity.
Price Chart
Executive Summary
BrightSpring Health Services reported Q2 2026 revenue of $3.873B (+23% YoY) and GAAP diluted EPS of $0.39, slightly below the $0.40 consensus. The company raised its full-year 2026 revenue guidance to $15.1B-$15.425B and Adjusted EBITDA guidance to $820M-$845M, reflecting strong operational momentum and the benefit of the Amedisys/LHC acquisition. The beat on guidance and continued deleveraging to 2.15x offset the marginal EPS miss, making this a fundamentally positive report.
Key Financial Metrics
Key Facts
- Q2 2026 revenue of $3.873B, up 23.0% YoY from $3.148B
- GAAP diluted EPS from continuing operations of $0.39 vs consensus $0.40 (2.5% miss)
- Adjusted EBITDA of $206M, up 44.2% YoY from $143M
- Full-year 2026 revenue guidance raised to $15.1B-$15.425B (17.0%-19.5% growth)
- Full-year 2026 Adjusted EBITDA guidance raised to $820M-$845M (32.8%-36.8% growth)
- Leverage reduced to 2.15x from 2.27x at Q1 2026; $300M debt paydown completed
- Pharmacy Solutions revenue grew 22% to $3.407B; Provider Services revenue grew 30% to $466M
- Home Health Care average daily census surged 54% to 46,448, driven by Amedisys/LHC acquisition
Financial Impact
Raised FY2026 revenue guidance by ~$650M at midpoint and Adjusted EBITDA guidance by ~$57.5M at midpoint vs prior guidance
Risk Factors
- Integration risk from the Amedisys/LHC acquisition and potential margin pressure from rising labor costs
- Medicare/Medicaid reimbursement rate changes could impact Pharmacy Solutions revenue per script growth
- Execution risk on achieving the upper end of raised guidance range given macro uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-326654 |
| Document: btsg-20260731.htm | 0001193125-26-326654 |
| Document: 0001193125-26-326654-index-headers.html | 0001193125-26-326654 |
| Document: 0001193125-26-326654-index.html | 0001193125-26-326654 |
| Document: 0001193125-26-326654.txt | 0001193125-26-326654 |
| 8-K Data (Synthetic) | 0001193125-26-326654 |
Track record
24 reports on BTSG
5 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +45.59% at T+60 after the Feb 27, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $71.36 Now $71.37 +0.01% settles Feb 12
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $67.15 Now $71.37 +6.28% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $65.86 Now $71.37 +8.37% settles Feb 3
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $66.89 Now $71.37 +6.70% settles Jan 28
- Oct 30, 202617d ago 8-K Bullish 6/10 No price data
- Oct 30, 202617d ago Press Release Neutral 5/10 Entry $66.89 Now $71.37 +6.70% settles Jan 28
- Oct 20, 202627d ago Institutional Cluster Neutral 3/10 Entry $62.36 Now $71.37 +14.45% settles Jan 19
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $57.26 Now $71.37 +24.64% settles Dec 28
- Aug 6, 202614w ago Institutional Cluster Bullish 6/10 Entry $60.60 to $66.89 Now $71.37 +17.77% ▲ +10.38% +12.05% vs SPY
- Jul 31, 202615w ago 8-K Bullish 7/10 Viewing No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers